Multiple Sclerosis, Rituximab, Hypogammaglobulinemia and Risk of Infections
Release Date:
Dr. Shuvro Roy talks with Dr. Annette Langer-Gould about the effective dose of rituximab and other B-cell depleting therapies in patients with multiple sclerosis, as well as important comorbidities to prevent infection risks. Read the related article in Neurology: Neuroimmunology and Neuroinflammation. Disclosures can be found at Neurology.org.
Multiple Sclerosis, Rituximab, Hypogammaglobulinemia and Risk of Infections